Ovarian Cancer Clinical Trial
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
Summary
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy.
PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in treating delayed nausea and vomiting in patients who are receiving chemotherapy for newly diagnosed childhood sarcoma, neuroblastoma, nasopharyngeal cancer, germ cell tumors, or Hodgkin lymphoma.
Full Description
OBJECTIVES:
Primary
Determine the efficacy of electroacupuncture, in terms of reducing acute and delayed chemotherapy-induced nausea, in patients with newly diagnosed pediatric sarcoma, neuroblastoma, nasopharyngeal carcinoma, or germ cell tumors.
Secondary
Determine the efficacy of this therapy, in terms of reducing delayed chemotherapy-induced emesis, in these patients.
Determine the efficacy of this therapy, in terms of altering salivary cortisol levels and fasting serum glucose and insulin levels as stress parameters, in these patients.
Determine the efficacy of this therapy, in terms of improving the quality of life, in these patients.
Determine the efficacy of this therapy, in terms of reducing acute nausea and emesis, in these patients.
OUTLINE: This is a multicenter, randomized, double-blind study. Patients are stratified according to planned treatment with cisplatin-based chemotherapy (yes vs no) and gender. Patients are randomized to 1 of 2 arms.
Arm I: Patients undergo electroacupuncture to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
Arm II: Patients undergo electroacupuncture to sham points on the arms and legs as in arm I.
Quality of life is assessed at baseline, on days 1 and 8 of each treatment course, and then after completion of the study.
PROJECTED ACCRUAL: A total of 65 patients (approximately 32 per arm) will be accrued for this study within 2.5-3 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Newly diagnosed malignancy of 1 of the following types:
Pediatric sarcoma
Neuroblastoma
Nasopharyngeal carcinoma
Germ cell tumor
Hodgkin lymphoma
Meets 1 of the following criteria:
Eligible for Children's Oncology Group (COG) protocol for sarcoma, neuroblastoma, or germ cell tumor
Eligible for NCI Pediatric Oncology Branch (POB) protocol for sarcoma
Following COG-approved standard treatment regimen for sarcoma, neuroblastoma, nasopharyngeal carcinoma, or germ cell tumor
Enrolled on the POB natural history protocol 98-C-0037
Planned treatment, according to COG or POB protocols, that includes a cisplatin- and/or doxorubicin-containing regimen for sarcoma, neuroblastoma, nasopharyngeal carcinoma, germ cell tumor, or Hodgkin lymphoma OR either a cyclophosphamide/ifosfamide-doxorubicin-containing or cyclophosphamide/dactinomycin-containing regimen for rhabdomyosarcoma
No clinical or radiographic signs of spinal cord compression
PATIENT CHARACTERISTICS:
Age:
5 to 35
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Platelet count greater than 50,000/mm^3 (transfusion independent)
No clotting disorders, including hemophilia
Hepatic:
PT and PTT normal (within 10% of institution's upper limit of normal)
Renal:
Not specified
Other:
Not pregnant
No casting of 1 or more extremities
No other condition that would preclude access to acupuncture points
No cognitive impairment
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
No prior systemic chemotherapy
Endocrine therapy:
More than 4 weeks since prior glucocorticoid therapy
No concurrent glucocorticoid therapy
Radiotherapy:
Not specified
Surgery:
Not specified
Other:
No prior acupuncture
No concurrent anticoagulants
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Bethesda Maryland, 20892, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.